In Reply Dr Long and colleagues point out that the SHINE trial1 may have shown additional useful results if patients were stratified based on prestroke glycemic control. Although the sample of patients without diabetes was small, eFigure 1 in Supplement 3 in the article showed that there was no significant difference in the primary outcome by treatment group in the subgroups of patients with or without diabetes. We are in the process of conducting secondary analyses to assess hemoglobin A1c levels and outcome.
Bruno A, Johnston KC, Durkalski-Mauldin VL, for the SHINE Trial Investigators. Treatment of Hyperglycemia in Patients With Acute Stroke—Reply. JAMA. 2019;322(22):2248–2249. doi:10.1001/jama.2019.16342
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: